DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy

Phase 1

Completed

Conditions: Sarcoma

Interventions: Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Other: Laboratory Biomarker Analysis
Radiation: Palliative Radiation Therapy

First Posted Date: 2014-12-18

Last Posted Date: 2017-07-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT02319824

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda

Phase 4

Completed

Conditions: HIV/AIDS and Infections

Interventions: Biological: Hepatitis B vaccine

First Posted Date: 2014-12-12

Last Posted Date: 2019-01-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 132

Registration Number: NCT02316444

Locations: 🇺🇬
Mulago National referral hospital, Kampala, Uganda

Blood Samples to Identify Biomarkers of Busulfan

Terminated

Conditions: Leukemia
Multiple Myeloma
Immunodeficiency
Myelodysplastic Syndrome
Lymphoma

First Posted Date: 2014-11-17

Last Posted Date: 2025-03-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 139

Registration Number: NCT02291965

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Phase 2

Active, not recruiting

Conditions: Secondary Myelofibrosis
Primary Myelofibrosis

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Methotrexate
Drug: Mycophenolate Mofetil
Drug: Ruxolitinib
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2014-09-29

Last Posted Date: 2025-04-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 61

Registration Number: NCT02251821

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

Not Applicable

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Device: Health Telemonitoring
Other: Questionnaire Administration
Other: Quality-of-Life Assessment
Procedure: Supportive Care

First Posted Date: 2014-08-27

Last Posted Date: 2020-01-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 24

Registration Number: NCT02226497

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Phase 2

Active, not recruiting

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Donor
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Childhood Acute Myeloid Leukemia in Remission
Myelodysplastic Syndrome With Excess Blasts-2
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Biphenotypic Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Drug: Thiotepa
Radiation: Total-Body Irradiation

First Posted Date: 2014-08-20

Last Posted Date: 2025-04-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 84

Registration Number: NCT02220985

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

Not Applicable

Completed

Conditions: Breast Carcinoma
Cancer Survivor
Depression
Fatigue
Malignant Bone Neoplasm
Sleep Disorder
Leukemia
Lymphoma
Malignant Female Reproductive System Neoplasm
Malignant Male Reproductive System Neoplasm

Interventions: Procedure: Management of Therapy Complications
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Behavioral: Telephone-Based Intervention

First Posted Date: 2014-07-16

Last Posted Date: 2020-10-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 390

Registration Number: NCT02192333

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

and more 3 locations

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Other: Laboratory Biomarker Analysis
Radiation: Radiation Therapy
Drug: TLR4 Agonist GLA-SE

First Posted Date: 2014-07-03

Last Posted Date: 2019-11-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT02180698

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Tocilizumab for Chronic Graft-versus-Host Disease Treatment

Phase 2

Withdrawn

Conditions: Graft Versus Host Disease

Interventions: Biological: tocilizumab
Other: laboratory biomarker analysis
Other: quality-of-life assessment

First Posted Date: 2014-06-25

Last Posted Date: 2016-05-06

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT02174263

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 2 locations

Malaria Clinical Trials Center General Screening

Completed

Conditions: Malaria

First Posted Date: 2014-04-21

Last Posted Date: 2020-09-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2101

Registration Number: NCT02119312

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy